Lupin Limited has received approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Prucalopride Tablets, 1 mg and 2 mg. The approved product is a generic version of Motegrity® tablets by Takeda Pharmaceuticals U.S.A. Inc., and will be manufactured at Lupin’s facility in Goa, India. Prucalopride is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.
Comments
Post a Comment